1000 mg 500 mg
Parameter Reference† Test* Reference‡ Test*
No. of subjects 26 26 25 25
Cmax, μg/ml 5.59 (1.76) 5.21 (1.60) 3.90 (1.25) 4.10 (1.31)
AUC0-t, h·μg/ml 20.10 (4.82) 18.87 (4.66) 12.49 (2.89) 12.48 (2.97)
AUC0-∞, h·μg/ml 20.85 (4.96) 19.53 (4.74) 13.04 (2.88) 13.14 (2.94)
Tmax, h 2.15 (0.75) 2.09 (0.61) 1.60 (0.63) 1.58 (0.73)
t1/2, h 2.46 (0.31) 2.52 (0.49) 2.60 (0.50) 2.59 (0.45)
AUC0-t = AUC from time 0 (baseline) to the last measurable concentration
AUC0-∞ = AUC from baseline extrapolated to infinity
*Trademark: Valextra® (Laboratorios Liomont, S.A. de C.V., Mexico City, Mexico)
†Trademark: Valtrex® (GlaxoSmithKline, Research Triangle Park, North Carolina)
‡Trademark: Rapivir® (GlaxoSmithKline Mexico, S.A.de C.V.,Mexico City, Mexico)
Table 1: Pharmacokinetic parameters of acyclovir after a single-dose administration of valacyclovir (500 mg or 1000 mg) in healthy Mexican adult subjects. Values are mean (SD).
Goto home»